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clarifying and updating ClinRO information. Methods: PROQOLID was searched on 
April 9, 2014 to retrieve current information about ClinROs using an advanced search 
engine. Results: The ClinRO information was found under the category “mode of 
administration” in the subcategory “clinician-rated.” Out of the 801 questionnaires 
in the database, fifty-two (6.5%) were identified as ClinROs. Out of these 52 ques-
tionnaires, nine were generic. Eight different therapeutic areas were identified (i.e., 
digestive system diseases, musculoskeletal diseases, neoplasms, nervous system 
diseases, respiratory tract diseases, psychiatric disorders, pathological conditions 
signs and symptoms, and skin and connective tissue diseases), representing 17 dif-
ferent indications, and 33.33% of the therapeutic areas included in PROQOLID (n= 24). 
The most represented therapeutic area was psychiatry (n= 23) followed by nervous 
diseases (n= 7). Only two questionnaires were specific to children: the Pediatric 
Evaluation of Disabilty Inventory and the WeeFIM®. To better individualize ClinRO 
information in PROQOLID, it is proposed to create a new meta-category, i.e., type of 
COA (PRO, ClinRO, ObsRO and PerfRO). It is also recommended to expand PROQOLID 
to all COAs. ConClusions: This review has shown that PROQOLID already includes 
ClinRO information. Recommendations are given on how to modify the organization 
and content of the database to present information on all COAs.
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objeCtives: Electronic Clinical Outcome Assessments (eCOAs) are increasingly 
being used in clinical trials and their use is encouraged by regulatory authorities. 
Licensing is a key issue for their appropriate utilization. The objective of this abstract 
is to make recommendations about eCOA licensing using lessons learned from the 
COA translation licensing. Methods: Publications about licensing of COA transla-
tions were searched and a review of the eCOAs specificities was performed using 
information available from e-vendors. Results: Very few publications exist about 
the licensing of COA translations. The ISOQOL TCA SIG has developed a draft reflec-
tion paper which considers that translations are derivative work of original ques-
tionnaires. As such, they recommend that the copyright of a COA and its translations 
should be owned by a unique entity, generally the original developer to harmonize 
and facilitate conditions of access and use. They state that distribution should be 
centralized to facilitate access to questionnaires, maintain reliable information 
about them, and control their use. Review of the e-vendors information shows that 
eCOAs are often customized, with proprietary devices and softwares, and cannot be 
shared across users. As a consequence, there is a multiplication of e-versions for a 
same content. Equivalence between paper and e-versions and between e-versions 
is then a major concern. The review also shows that migration from paper to the 
electronic platform/device implies changes to the content and format of the paper 
version. Therefore the eCOAs can be considered as derivative works of an original 
COA and lessons learned from copyright of translations may apply. Examples will 
be provided. ConClusions: Centralized copyright ownership by the owner of the 
original COA and centralized licensing process for eCOAs should be discussed with 
all stakeholders to help controlling use and users and to protect the integrity of 
the instrument across e-versions by providing clear rules of e-implementation.
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objeCtives: To determine how European databases are used to support pharmaco-
epidemiological research. Randomised, controlled trials remain the gold standard 
for evaluation of drug efficacy and safety. However, the only way of identifying treat-
ment pathways and improving understanding of real world costs and outcomes at 
different stages of care is via longitudinal observational studies. Observational data 
from electronic health records (EHRs) are essential to this pharmaco-epidemiologi-
cal research. Different European databases have different strengths in terms of data 
types and availability. Identifying these strengths will help to select the right data-
base for a particular study. In this context, one approach to increasing our under-
standing is to analyse types of published data to determine how databases have 
historically been used to support research. Methods: We identified peer-reviewed 
publications over the last 10 years from one popular longitudinal general practice 
patient database with some secondary care links. The publications were assigned 
to disease areas and study types (e.g. prevalence, resource utilisation, treatment 
patterns, outcomes etc). Results: Based on this mapping exercise, we identified 
the types of studies and the disease areas that this European database commonly 
supports. We also highlight gaps in disease area coverage and types of real world 
evidence studies and discuss potential reasons for this underuse. ConClusions: 
European observational data from EHRs provide increasingly important information 
for stakeholders of new treatment, however there are still a number of gaps in terms 
of disease areas and study types that these databases can support.
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objeCtives: The lack of accessible, comprehensive sources of medical and quality 
of life data in Germany has partially hindered the ability to research diabetes clinical 
practice. The aim of this study was to build a prospective, national, multi-centre Type 
2 diabetes mellitus (T2DM) registry using an innovative data collection methodol-
ogy to better understand the disease specific epidemiology, treatment patterns and 
scenario analysis was employed. PSA cut-off levels were varied between > 3ng/ml 
and > 4ng/ml reflecting European guidance and practice variation in Ireland. Costs 
and benefits were discounted at 5% per annum. Results: Extensive probabilistic 
sensitivity analyses highlighted wide variation in incremental cost-effectiveness 
ratios (ICERs). PSA testing may be cost effective using a once-off test at age 50 or age 
55 depending on the ceiling ratio incorporated. Results for the ≥ 3ng/ml PSA cut-off 
consistently dominated those for the ≥ 4ng/ml PSA cut-off. ConClusions: This 
analysis illustrates the value MPES methods for economic modelling of interven-
tions. The results contribute to the ongoing accumulation of evidence on the costs 
and benefits of PSA testing internationally.
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objeCtives: Despite advances in chronic lymphocytic leukemia (CLL) treatment, 
roughly 25% of first and 50% of second line patients experience relapse. Relapse, 
however, is not well coded in claims data and is not well documented in EMR data 
due to under reporting of patient status, variability in terminology used to report 
patient status, and change in disease progression over time. The goal of this analysis 
was to develop an algorithm to identify relapsed patients when patient status is 
not clearly documented. Methods: CLL patients in the MarketScan® Oncology 
EMR Database with recorded patient status were identified. Relapse was explored 
using two methods: 1) recorded patient status of relapse; 2) changes in laboratory 
data. For the first phase of algorithm development, both indications of relapse were 
compared to the date of treatment initiation. Laboratory data included lymphocytes, 
platelets, and hemoglobin. Results: Of 18,334 patients with CLL, 7,865 (43%) had 
any patient status reported. 528 had any mention of either relapse or remission 
and 73 (1%) patients had a record for relapse on the same date as a CLL diagnosis 
and no evidence of any other cancer types. For these 73 patients, the date of new 
treatment initiation had no relationship with the date of the first recorded relapse. 
Among these same patients, declines in hemoglobin and platelets, and increases in 
lymphocytes preceded treatment initiation by several days. ConClusions: Patient 
status does not appear to be updated regularly and documented status may not 
indicate decision to treat. This preliminary work suggests that lab data provide a 
viable source for algorithm development as they are regularly reported in the EMR 
and for CLL are likely linked to decision to treat. Next steps include determining 
the specific rule for identifying the change in lab values that triggers treatment 
initiation or resumption.
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objeCtives: Evaluating effectiveness of oncological treatments and their costs 
becomes more and more important with respect to the high burden of malignant 
diseases. The aim of this research was to estimate the occurrence, survival and 
health care cost of colorectal-, breast-, prostate- and lung cancer patients based on 
the National Health Insurance Fund (NHIF) database. Methods: Survival and cost 
analyses were performed on the NHIF database. Inclusion criteria: at least two con-
secutive ICD codes between 2000 and 2012, with a minimum of 30 days difference; 
or those with one ICD code, followed by death within 60 days. The following ICDs 
were considered: C18-C20 (colorectal), C33-C34 (lung), C50 (breast), C61 (prostate). 
428 860 social security numbers met our inclusion criteria. The following indicators 
were estimated: number of new cases, mortality, time from diagnosis to treatment, 
survival and annual costs related and not related to the disease. Results: In 2011, 
the numbers of new cases were the following: colorectal cancer: 7299 breast cancer: 
5842, prostate cancer: 3162, and lung cancer: 5499. The probability of 5-year over-
all survival from first diagnosis were 41.3%, 75.2%, 62.1% and 17.1%, respectively. 
Median time from first diagnosis to treatment initiation was less than 1 month 
in colorectal-, breast- and prostate cancer and less than 2 months in lung cancer. 
Annual cost of patient was 3166 EUR (colorectal cancer), 2585 EUR (breast cancer), 
2833 EUR (prostate cancer) and 4158 EUR (lung cancer), respectively (2011 average 
exchange rate: 279.21 HUF/EUR). These figures indicate that annual cost of care of 
these malignant patients are less than half of the annual cost of kidney transplanted 
and haemophilia patients estimated with similar methodology. ConClusions: 
Data suggest that payer’s database is suitable for estimating epidemiologic and 
economic indicators of malignant disorders. Payer’s database analysis can support 
evidence-based policy-making.
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objeCtives: In 2002, PROQOLID was launched to provide an overview of existing 
PRO instruments. In October 2011, the term Clinical Outcome Assessments (COAs) 
was introduced to better reflect the importance of the source of information in 
measurements: patients (PROs), clinicians (ClinROs), and observers (ObsROs). In May 
2013, a new category was added: Performance outcome assessments (PerfOs). With 
this evolving taxonomy, including information about all COAs might become a cru-
cial step in developing PROQOLID. The objective of this study was: (1) To review how 
ClinROs are currently reported in PROQOLID; and (2) To propose (if needed) ways of 
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has been believed that EMR system improved efficacy of the hospital. But a pure 
hospital management/financial meaning of EMR is still not clear. It is said that the 
total costs for maintaining EMR are 2-5% of medical revenue and they are continu-
ously needed. In Japan, in order to increase the efficiency of a clinical trial/research, 
government is planning to set up one big virtual hospital using EMR and IT tech-
nology. In this study, we analyze the change in financial condition and the price of 
EMR system. Methods: From the hospital website and financial statement, we 
checked when and whether EMR was introduced. Then we analyzed the change 
in financial condition of the hospital that introduced EMR with the hospital that 
did not introduce EMR using the financial statements of 143 hospitals in National 
Hospital Organization (NHO). The information of the EMR price was obtained from 
the government website. Results: In 2011, there were 44 hospitals that had intro-
duced EMR. Comparing the financial condition between the hospital with EMR and 
the hospital without EMR, there was 1% or more of difference in medical revenue. 
The average price of EMR for 1 year per 1 bed was US$328.8. ConClusions: The 
result demonstrated that the price of all EMR system did not improve hospital 
finance and efficiency. Because of the high cost EMR system, making one big virtual 
hospital using IT technology is still difficult. Therefore, we need more cost effective 
and easy EMR system.
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objeCtives: To support tariff setting of Diagnosis Related Groups in the 
Netherlands, the hospital services of each patient are systematically collected in 
a national database. This database may also serve as an important data source 
for economic evaluations. Our study assessed the feasibility of the database to 
support economic evaluations. Methods: Treatment costs for acute myocardial 
infarction (AMI) and breast cancer were determined for 2012 from the hospital 
perspective, with the national database as the primary data source. Results: 
Using the national database as a primary data source for economic evaluations 
has several limitations. Firstly, the database does not contain unit costs of hos-
pital services. Thus, we had to rely on alternative data sources such as reference 
prices. Secondly, the establishment of relevant patient-subgroups is not always 
possible because only few clinical parameters are recorded. Although we were 
able to identify relevant patient subgroups for AMI (ST segment vs non-ST seg-
ment elevated patients and PCI vs conventional treatment), this was not possible 
for breast cancer where different stages of disease could not be distinguished. 
Lastly, some resource quantities, such as medications and medical devices, are 
not routinely collected. ConClusions: Using the national database as the input 
of resource quantities in economic evaluations may result in valid cost estimates, 
especially when relevant subgroups can be identified. The cost assessment of AMI 
has proven that the database enables the collection of resource quantities for 
individual patients from a single data source and thus increases the comparability 
of health economic outcomes.
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objeCtives: To evaluate the burden of influenza B in terms of hospitalizations 
and deaths in France. Methods: The analysis of the impact of influenza B used 3 
French databases 1) hospitalization for respiratory diseases, 2) deaths resulting from 
cardiorespiratory disease, and 3) information on circulating strains. The analysis 
covered the period 2003 through to 2011. The study is based on an indirect approach 
of modeling where hospitalization, mortality and virology time series data will be 
extracted as monthly or weekly aggregated information. The numbers of hospi-
talizations and deaths attributable to influenza B were determined from positive 
virological analysis through a regression model (considering all influenza circulat-
ing strains classified by type and subtype) firstly over the total French population, 
and then by age category (0-4 years, 5-12, 15-64, 65 and above). A second method to 
estimate the excess of hospitalizations and deaths during influenza epidemic peri-
ods vs. non-epidemic periods was also used. Results: Over the period 2003-2011, 
nearly 28,000 hospitalizations and 12,000 deaths on average were associated with 
influenza each year. The percentages of hospitalizations and deaths attributable 
to influenza B were 33% (9,200) and 34% (4,000) respectively, amongst the overall 
population. These were observed predominantly in the elderly (> 65 years): 66% of 
hospitalizations and 94% of deaths. The two methods used show similar results, 
with a difference globally of less than 5%. ConClusions: On average each year 
around 9,200 hospitalizations and 4,000 cardiorespiratory deaths are associated 
with epidemics of influenza B in France.
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objeCtives: To identify the long term effects of common symptoms of pregnancy 
and whether these increase the risk of cardiovascular disease or symptoms asso-
ciated with it in women at 21 years after pregnancy. Methods: Data used were 
from the Mater University Study of Pregnancy (MUSP), a community- based pro-
spective birth cohort study begun in Brisbane, Australia, in 1983. Chi square test 
and logistic regression analyses were conducted. Results: Data were available for 
3692 women. In cross tabulations, morning sickness, heartburn and backache show 
patient reported outcomes (PRO). Methods: From the physician universe of the 
IMS®Disease Analyzer (1,500 diabetologists and 57,500 general practitioners), a sub-
set of 101 physicians have agreed to participate. Pre-programmed inclusion criteria 
(i.e. ≥ 18 years old with T2DM diagnosis) triggers consecutive patient selection for 
further data collection. A custom software-based electronic case report form (eCRF) 
is completed once per quarter by the physician to capture further diabetes informa-
tion. Patients complete a validated set of PROs at physician office every 6 months. 
Anonymised data from the electronic medical record (EMR), eCRF and PRO are linked 
through a unique process to ensure patient confidentiality. Results: A total of 1,029 
T2DM patients are contributing to the registry (at June 2014). Preliminary analysis 
of the DIAREG cohort has shown comparable representativeness to IMS®Disease 
Analyzer for several patient characteristics: age, gender, distribution of T2DM treat-
ment and physician type. The DIAREG improves research use of the EMR data by 
filling in missing information for weight, blood pressure and HbA1C (e.g. complete-
ness of HbA1C records improved from 42.3% to 83.3% of patients). The DIAREG 
enhances breadth of information by collecting data that is not normally captured 
in EMR sources, such as physician rationale related to treatment choice or switch, 
target HbA1C, hypoglycaemic events, occurrence of micro or macrovascular events, 
and patient reported information (e.g. quality of life, treatment satisfaction and 
depression). ConClusions: DIAREG enables unique capability to research T2DM 
in Germany through multiple linked longitudinal data sources.
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objeCtives: Health care utilization databases or electronic medical records can be 
very useful to study the use and outcomes of pharmacological and therapeutical 
measures. There is little information on the availability and accessibility of these 
types of databases for health and disease management in the Asian Pacific Region. 
This study is performed to gain more insight in the availability and accessibility 
of health care utilization databases in AsiaPac. Methods: Searches were done 
using Google Scholar, PubMed, ISPOR’s International Digest of Databases and refer-
ences in publications. Different types of databases were included in the overview, 
including health insurance databases, claims databases and electronic medical 
records from primary care of hospitals. Information extracted was: type of database, 
short description, population covered, start of data collection, variables included, 
accessibility, URL and English language yes/no. Countries included were Australia, 
China, Japan, South Korea, Malaysia, Singapore and Thailand. Results: Most of the 
databases originate in Japan and Australia. Taiwan and South Korea have a large 
health insurance databases covering ~98% of the population. Limited number of 
databases is available in the other countries investigated. Accessibility could only be 
derived from the websites that provide an English translation. From these websites 
it appears that accessibility to these databases is often limited for health policy 
makers and researchers due to privacy protection issues. ConClusions: Several 
valuable health care utilization databases exist in the Asian Pacific region. These 
databases could be very valuable in drug utilization and health outcomes research 
if easily available to all researchers.
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objeCtives: The Brazilian Network for Health Technology Assessment (REBRATS) 
spreads the HTA culture in health services and academic institutions, and also 
supports policy makers and managers in the decision-making process. It works 
through six working groups that prioritizes HTA settings and themes; develops 
methodological guidelines; trains professionals; and manage and disseminates 
information. This study aims to demonstrate REBRATS´s advances based on the 
productivity of the network members. Methods: Analysis of the network per-
formance through the number of publications available on the REBRATS data-
base; number of accesses to the REBRATS webpage obtained through the access 
tool and data extraction by Google Analytics, monitoring the participation on the 
REBRATS social networking and computing new network members. Results: 
Since REBRATS´ implementation in 2008, it was made available on its website 62 
publications including Guidelines, HTA Bulletins and others, and 364 studies in 
its database. In 2014, 64 institutions are already member of the network, repre-
senting an increase of over 45% compared to 2008. Additionally, the site began 
to be tracked in mid-2012, when the average number of accesses was 36,659 and 
approximately 2037 per monthly in more than 85 countries. Since March 2012, 
when REBRATS social network on Facebook was created, there have been more 
than 300 published news with approximately 43,891 views and an average of 143 
visualizations per issue reported by the network. ConClusions: The strategies 
for advertising the network and disseminate the HTA products produced by its 
members have contributed significantly to the advance of HTA in Brazil, beyond 
the reach of people interested in this research field. Efforts should be directed 
towards advertising the production internationally.
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objeCtives: Ministry of Health, Labour and Welfare (MHLW) of Japan announced 
the rule about electronic preservation of a medical record in 1999. Then, introduc-
tion of Electric Medical Record (EMR) into a hospital was started. Government set 
a target of diffusion rate of EMR to 60% in 2006, but the result was only 20-30%. It 
